The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Engineering nanoparticles to locally activate T cells in the tumor microenvironment
Abstract
Engineered antibody nanoparticles overcome immunological tolerance to PDL1 blockade therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Photodynamic therapy and anti-tumour immunity
Castano, A. P., Mroz, P., & Hamblin, M. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1894 · Cited by 2,676
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016) · Nature Communications · doi:10.1038/ncomms13193 · Cited by 1,596
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Classifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,411
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 1×
“INTRODUCTION Immune checkpoint blockade (ICB) therapy is emerging as a promising approach for cancer immunotherapy by modulating the immunosuppressive tumor microenvironment (1, 2).”
BackgroundMuro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,121
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Chen, Q., Wang, C., Zhang, X., Chen, G., Hu, Q., Li, H., Wang, J., Wen, D., Zhang, Y., Lu, Y., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0319-4 · Cited by 1,010
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Brown, J. A., Dorfman, D. M., Ma, F.-R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., & Freeman, G. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1257 · Cited by 968
A STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 900
Self-citationSharabi, A. B., Lim, M., DeWeese, T. L., & Drake, C. G. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00007-8 · Cited by 899
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S., & Stephan, M. T. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.57 · Cited by 785
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H., & Gu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.5b05030 · Cited by 784
He, C., Duan, X., Guo, N., Chan, C., Poon, C., Weichselbaum, R. R., & Lin, W. (2016) · Nature Communications · doi:10.1038/ncomms12499 · Cited by 754
Sheng, Z., Hu, D., Zheng, M., Zhao, P., Liu, H., Gao, D., Gong, P., Gao, G., Zhang, P., Ma, Y., et al. (2014) · ACS Nano · doi:10.1021/nn5062386 · Cited by 719
Lu, K., He, C., Guo, N., Chan, C., Ni, K., Lan, G., Tang, H., Pelizzari, C., Fu, Y.-X., Spiotto, M. T., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0203-4 · Cited by 596
Epidermal Viral Immunity Induced by CD8α + Dendritic Cells But Not by Langerhans Cells
Allan, R. S., Smith, C. M., Belz, G. T., van Lint, A. L., Wakim, L. M., Heath, W. R., & Carbone, F. R. (2003) · Science · doi:10.1126/science.1087576 · Cited by 567
Moynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J. M., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 524
Wang, D., Wang, T., Liu, J., Yu, H., Jiao, S., Feng, B., Zhou, F., Fu, Y., Yin, Q., Zhang, P., et al. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b01994 · Cited by 405
Self-citationYe, Y., Wang, J., Hu, Q., Hochu, G. M., Xin, H., Wang, C., & Gu, Z. (2016) · ACS Nano · doi:10.1021/acsnano.6b04989 · Cited by 339
Hu, Q., Sun, W., Wang, J., Ruan, H., Zhang, X., Ye, Y., Shen, S., Wang, C., Lu, W., Cheng, K., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0310-2 · Cited by 310
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity
Garg, A. D., Nowis, D., Golab, J., & Agostinis, P. (2010) · Apoptosis · doi:10.1007/s10495-010-0479-7 · Cited by 297
PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy
Zhang, X., Wang, C., Wang, J., Hu, Q., Langworthy, B., Ye, Y., Sun, W., Lin, J., Wang, T., Fine, J., et al. (2018) · Advanced Materials · doi:10.1002/adma.201707112 · Cited by 290
Self-citationZhu, G., Mei, L., Vishwasrao, H. D., Jacobson, O., Wang, Z., Liu, Y., Yung, B. C., Fu, X., Jin, A., Niu, G., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01386-7 · Cited by 255
Engineering PD-1-Presenting Platelets for Cancer Immunotherapy
Zhang, X., Wang, J., Chen, Z., Hu, Q., Wang, C., Yan, J., Dotti, G., Huang, P., & Gu, Z. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02321 · Cited by 232
Quantitative Imaging of Lymphatic Function with Liposomal Indocyanine Green
Proulx, S. T., Luciani, P., Derzsi, S., Rinderknecht, M., Mumprecht, V., Leroux, J.-C., & Detmar, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0271 · Cited by 212
Aguiar, P. N., De Mello, R. A., Hall, P., Tadokoro, H., & Lima Lopes, G. D. (2017) · Immunotherapy · doi:10.2217/imt-2016-0150 · Cited by 197
A Dual Immunotherapy Nanoparticle Improves T‐Cell Activation and Cancer Immunotherapy
Mi, Y., Smith, C. C., Yang, F., Qi, Y., Roche, K. C., Serody, J. S., Vincent, B. G., & Wang, A. Z. (2018) · Advanced Materials · doi:10.1002/adma.201706098 · Cited by 196
Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy
Yuan, H., Jiang, W., von Roemeling, C. A., Qie, Y., Liu, X., Chen, Y., Wang, Y., Wharen, R. E., Yun, K., Bu, G., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.69 · Cited by 172
Awuah, S. G., Zheng, Y.-R., Bruno, P. M., Hemann, M. T., & Lippard, S. J. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b10182 · Cited by 164
LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors
Luo, G., Yu, X., Jin, C., Yang, F., Fu, D., Long, J., Xu, J., Zhan, C., & Lu, W. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.10.014 · Cited by 161
Cano‐Mejia, J., Burga, R. A., Sweeney, E. E., Fisher, J. P., Bollard, C. M., Sandler, A. D., Cruz, C. C., & Fernandes, R. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.10.015 · Cited by 146
Lei, C., Liu, P., Chen, B., Mao, Y., Engelmann, H. E., Shin, Y., Jaffar, J., Hellström, I., Liu, J., & Hellström, K. E. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102414t · Cited by 117
Rahimian, S., Fransen, M. F., Kleinovink, J. W., Amidi, M., OSSENDORP, F. A., & Hennink, W. E. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.043 · Cited by 100
Zheng, Y., Yin, G., Le, V., Zhang, A., Chen, S., Liang, X., & Liu, J. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.12852 · Cited by 95
Synthesis and bioactivity of a conjugate composed of green tea catechins and hyaluronic acid
Lee, F., Lim, J., Reithofer, M. R., Lee, S. S., Chung, J. E., Hauser, C. A. E., & Kurisawa, M. (2015) · Polymer Chemistry · doi:10.1039/c5py00495k · Cited by 46
Cancer Evolution during Immunotherapy
Andrews, M. C., & Wargo, J. A. (2017) · Cell · doi:10.1016/j.cell.2017.10.027 · Cited by 33
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Enantiomer-dependent immunological response to chiral nanoparticles
Xu, L., Wang, X., Wang, W., Sun, M., Choi, W. J., Kim, J.-Y., Hao, C., Li, S., Qu, A., Lu, M., et al. (2022) · Nature · doi:10.1038/s41586-021-04243-2 · Cited by 641
Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy
Ji, B., Wei, M., & Yang, B. (2022) · Theranostics · doi:10.7150/thno.67300 · Cited by 544
Song, R., Li, T., Ye, J., Sun, F., Hou, B., Saeed, M., Gao, J., Wang, Y., Zhu, Q., Xu, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202101155 · Cited by 308
Self-citationMolecular and nanoengineering approaches towards activatable cancer immunotherapy
Zhang, C., & Pu, K. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00773c · Cited by 302
Metadata
- Authors
- Wang, D., Wang, T., Yu, H., Feng, B., Zhou, L., Zhou, F., Hou, B., Zhang, H., Luo, M., & Li, Y.
- Venue
- Science Immunology
- Published
- 2019-07-05
- Volume
- 4
- Issue
- 37
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W2958502160
- Cited by
- 261
- References
- 59
- FWCI
- 13.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.